Retinitis Pigmentosa (RP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Retinitis Pigmentosa (RP) Marketed and Pipeline Drugs Report Overview
Retinitis pigmentosa (RP) is a cluster of rare eye conditions. One of these conditions causes degeneration of the retina, the light-sensitive layer at the back of the eye. This degeneration results in a progressive loss of vision. Retinitis pigmentosa is an inherited genetic disorder. Most people have progressive vision loss over time, with symptoms usually starting in childhood. While there isn’t a cure at this time, people can maximize their residual vision with the help of a variety of vision aids and rehabilitation programs.
Key Mechanisms of Action (Marketed) | · Receptor Agonist
· Enzyme Activator |
Key Routes of Administration (Marketed) | · Injection
· Oral |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Retinitis Pigmentosa (RP) marketed, and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Retinitis pigmentosa.
The report also provides actionable insights into the clinical and commercial landscapes of Retinitis Pigmentosa (RP)drugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
Key Mechanisms of Action (Pipeline) | · Protein & Peptide Activator
· Receptor Activator · Enzyme Activator · Enzyme Inhibitor · Receptor Agonist |
Key Molecule Types (Pipeline) | · Biologic
· Small Molecule · Oligonucleotide |
Key Routes of Administration (Pipeline) | · Injection
· Topical · Oral · Inhalational |
Top Sponsors (Marketed and Pipeline Drugs) | · ProQR Therapeutics NV
· jCyte Inc. · Ankara University Technopolis · Johns Hopkins · Johnson & Johnson |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Retinitis Pigmentosa (RP) Marketed Drugs Market Segmentation by Mechanisms of Action
The key MoA of the marketed drugs for Retinitis Pigmentosa (RP) include receptor agonist and enzyme activator. Most of the marketed drugs followed receptor agonist MoA in 2023 in the Retinitis Pigmentosa (RP)market.
Retinitis Pigmentosa (RP) Marketed Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of Retinitis Pigmentosa (RP) Marketed Drugs
Retinitis Pigmentosa (RP) Marketed Drugs Market Segmentation by Routes of Administration
The key RoA of Retinitis Pigmentosa (RP)marketed drugs include injection and oral. Most marketed drugs for Retinitis Pigmentosa (RP) were injection therapies.
Retinitis Pigmentosa (RP)Marketed Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of Retinitis Pigmentosa (RP) Marketed Drugs
Retinitis Pigmentosa (RP) Pipeline Drugs Market Segmentation by Mechanisms of Action
The key MoA of the drugs in the Retinitis Pigmentosa (RP) pipeline mainly includes protein & peptide activator, receptor activator, enzyme activator, enzyme inhibitor, and receptor agonist among others. Most of the pipeline drugs for RP followed protein & peptide activator MoA in 2023.
Retinitis Pigmentosa (RP) Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of Retinitis Pigmentosa (RP) Pipeline Drugs
Retinitis Pigmentosa (RP) Pipeline Drugs Market Segmentation by Routes of Administration
The key RoA of the drugs in the Retinitis Pigmentosa (RP) pipeline mainly includes injection, topical, oral, and inhalational. In 2023, most pipeline drugs for Retinitis Pigmentosa (RP) were injection therapies.
Retinitis Pigmentosa (RP) Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of Retinitis Pigmentosa (RP) Pipeline Drugs
Retinitis Pigmentosa (RP) Pipeline Drugs Market Segmentation by Molecule Types
In 2023, the leading molecule type for Retinitis Pigmentosa (RP) pipeline drugs was biologic, followed by a small molecule. The other drugs currently in development are also oligonucleotide types.
Retinitis Pigmentosa (RP) Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of Retinitis Pigmentosa (RP) Pipeline Drugs
Retinitis Pigmentosa (RP) Marketed and Pipeline Drugs Market – Competitive Landscape
A few of the top sponsors in the Retinitis Pigmentosa (RP) marketed and pipeline drugs market are ProQR Therapeutics NV, jCyte Inc., Ankara University Technopolis, Johns Hopkins, and Johnson & Johnson among others. ProQR Therapeutics NV sponsored the highest number of trials in 2023.
Retinitis Pigmentosa (RP) Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy Full Report for More Sponsor Insights into the Retinitis Pigmentosa (RP) Marketed and Pipeline Drugs Market
Segments Covered in the Report
Retinitis Pigmentosa (RP) Marketed Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Receptor Agonist
- Enzyme Activator
Retinitis Pigmentosa (RP) Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Protein & Peptide Activator
- Receptor Activator
- Enzyme Activator
- Enzyme Inhibitor
- Receptor Agonist
Retinitis Pigmentosa (RP) Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologic
- Small Molecule
- Oligonucleotide
Scope
The key components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Understand the trends shaping and driving the Retinitis Pigmentosa (RP)market to develop business strategies.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Retinitis Pigmentosa (RP)market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Novartis
Neurotech Pharmaceuticals
Novelion Therapeutics
jCyte
Ocugen
Innovations In Sight
Horama
Neurotech Pharmaceuticals
Allergan
Table of Contents
Frequently asked questions
-
Which was the leading MoA for Retinitis Pigmentosa (RP) marketed drugs in 2023?
Most of the drugs followed receptor agonist MoA in 2023 in the Retinitis Pigmentosa (RP) drugs market.
-
Which was the leading MoA for Retinitis Pigmentosa (RP) pipeline drugs in 2023?
In 2023, most of the drugs followed protein & peptide activators in the Retinitis Pigmentosa (RP) drugs market.
-
Which was the leading molecule type for Retinitis Pigmentosa (RP) pipeline drugs in 2023?
In 2023, most of the drugs in development for Retinitis Pigmentosa (RP) were biologics.
-
Which are the top sponsors in the Retinitis Pigmentosa (RP) marketed and pipeline drugs market?
A few of the top sponsors in the Retinitis Pigmentosa (RP) marketed and pipeline drugs market are ProQR Therapeutics NV, jCyte Inc., Ankara University Technopolis, Johns Hopkins, and Johnson & Johnson among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.